Healthcare
Live Price
Offline$0.56
+0.00% today
1Y Change
-9.68%
Window
Jun 25, 2025 → Jun 18, 2026
Coverage: 247 bars · Jun 25, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Bangkok Dusit Medical Services Public Company Limited (BDULF) is a Healthcare stock with a market cap of $294.00B. The stock last traded around $0.56 and down 9.7% across the available one-year price window (Jun 25, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +3.3%, EPS growth of -1.0%, a dividend yield of 5.4%. What stands out right now is revenue +3.3%, EPS -1.0%, free cash flow +15.5% with operating margin 17.3% and ROIC 11.1%. The dividend matters to the case here, with a current yield around 5.4%. Valuation is more restrained than many high-expectation growth names at P/E 18.6 and price/sales 2.6. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines BDULF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BDULF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BDULF Max Drawdown
-15.15%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BDULF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$74.5B
-19.0% YoY
FY Net Income
$7.9B
-37.0% YoY
Free Cash Flow
$10.2B
-32.9% YoY
Revenue Growth
+3.3%
EPS Growth
-1.0%
Gross Margin
36.1%
Net Margin
14.2%
Income statement
THB
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 111.4B | 107.9B | 100.9B | 91.9B | 74.5B |
| Gross Profit | 38.9B | 39.8B | 37.4B | 33.6B | 25.0B |
| Operating Income | 18.4B | 20.5B | 18.9B | 17.0B | 11.2B |
| EBITDA | 25.3B | 26.9B | 25.0B | 23.1B | 17.6B |
| Net Income | 15.8B | 16.0B | 14.4B | 12.6B | 7.9B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
THB
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6.3B | 7.4B | 7.8B | 12.7B | 10.9B |
| Total Assets | 157.8B | 151.5B | 143.6B | 141.5B | 128.5B |
| Total Liabilities | 47.9B | 47.6B | 44.7B | 47.8B | 40.7B |
| Shareholder Equity | 105.8B | 100.0B | 95.4B | 89.9B | 83.8B |
| Total Debt | 17.5B | 18.4B | 18.1B | 23.6B | 18.8B |
| Net Debt | 11.2B | 11.0B | 10.3B | 10.9B | 7.9B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
14.6B
-28.2% YoY
Capital Expenditures
4.4B
+13.8% YoY
Free Cash Flow
10.2B
-32.9% YoY
Key ratios
Gross Margin
36.1%
Operating Margin
17.3%
Net Margin
14.2%
ROE
15.4%
Debt / Equity
0.24x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.